Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Cutia Therapeutics ( (HK:2487) ).
Cutia Therapeutics announced that non-executive director Dr. Huang Xiao will resign from the board with effect from 30 December 2025 to focus on personal commitments, with both the company and Dr. Huang confirming there are no disagreements or issues requiring shareholder attention. On the same date, the company will appoint industry veteran Mr. Lu Minfang, a partner at Yunfeng Investment Management and former chief executive of China Mengniu Dairy, as a non-executive director for an initial three‑year term without director’s fees, bringing extensive leadership and consumer-sector experience that may strengthen Cutia’s governance and strategic positioning.
The most recent analyst rating on (HK:2487) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on Cutia Therapeutics stock, see the HK:2487 Stock Forecast page.
More about Cutia Therapeutics
Cutia Therapeutics, listed on the Hong Kong Stock Exchange, operates in the healthcare and biopharmaceutical sector, focusing on the development and commercialisation of therapeutic products. The group manages its operations through subsidiaries and is governed by a board comprising executive and non-executive directors who oversee its strategic direction and corporate governance.
Average Trading Volume: 377,828
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.9B
For a thorough assessment of 2487 stock, go to TipRanks’ Stock Analysis page.